May 31, 2025 08:00 AM EDT
R&D

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

Elizabeth Cairns

Senior biopharma journalist

Af­ter Pfiz­er spent $1 bil­lion up­front to li­cense a tar­get­ed pro­tein de­grad­er from Arv­inas, the lat­est clin­i­cal re­sults sug­gest that the drug over­all is no …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

As­traZeneca de­tails its oral SERD 'switch­ing' reg­i­men as fea­si­bil­i­ty ques­tions re­main

Take­da, Pro­tag­o­nist un­veil ple­nary da­ta for po­ten­tial block­buster rare blood dis­ease drug

As life-sav­ing check­point drugs move to ear­li­er can­cers, re­searchers de­bate how best to use them

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times